英国与多间药厂签订9,000万剂新冠疫苗协议
英国商业、能源及工业策略大臣岑浩文已经与辉瑞、BioNTech以及法国疫苗厂商Valneva签署协议,将获得9,000万剂两种新冠疫苗。
根据协议,英国已取得3,000万剂BioNTech 及辉瑞的实验性疫苗,并原则上获得6,000万剂Valneva疫苗,如果该疫苗被证明是安全及有效,则可以再选择购买4,000万剂。
英国还表示,已从阿斯利康获得新冠病毒的抗体治疗,以保护无法接种疫苗的人士。
受消息刺激,疫苗股於美国盘前显着抽升,BioNTech现升6.1%,Vaccinex涨17%,IBio更大升34.3%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.